Phesi’s new global analysis shows more than 100 diseases are being studied using GLP-1 therapies with potential for patient benefits to extend far beyond obesity, opening doors to a new era of multi-disease prevention and care.
Inside the report:
The top 20 indications where GLP-1 receptor antagonists are being studied
Phesi’s GLP-1 Digital Patient Profile constructed using contextualised real-world data
Implications for clinical development and healthcare strategies
